Amplia Therapeutics incoming chairman Ms Jane Bell AM Amplia Therapeutics (ASX: ATX) has refreshed its board, handing the chairman's role to experienced life sciences director Jane Bell AM as the Melbourne-based drug developer looks to convert encouraging clinical momentum into regulatory and commercial success. The company has framed the transition as part of a planned board renewal and succession process, timed to align with a genuine inflection point for its lead dru

Amplia Therapeutics’ business development team recently attended the prestigious 2026 American Society of Clinical Oncology conference in Chicago, USA. While many cancer companies spend billions trying to make stronger chemotherapies, Melbourne-based Amplia Therapeutics (ASX: ATX) is taking a different path, developing a “shield-breaking” treatment that makes other multi-billion-dollar drugs work better. Following the world's premier American Society of Clinical Oncolog

Amplea Therapeutics managing director and chief executive officer Dr Chris Burns. For everyday punters looking at medical technology companies, the best opportunities often come from identifying a drug that makes other multi-billion-dollar treatments work better. That is the main idea behind Melbourne-based medical company Amplia Therapeutics (ASX: ATX). While most cancer companies spend billions trying to make stronger, more toxic chemotherapies, Amplia is taking a dif

Amplia Therapeutics and the Australia New Zealand Gynaecological Group have announced a new ovarian cancer study. ASX-listed Amplia Therapeutics (ASX: ATX) is aggressively broadening its clinical reach, unveiling a major new collaboration to throw its lead drug candidate, narmafotinib, into the ring against ovarian cancer. The company has inked a deal with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to launch a new clinical study to evaluate its pro

This week’s Bulls N’ Bears ASX Runners of the Week is… Amplia Therapeutics, after the company unveiled results for a potential golden bullet for pancreatic cancer.